Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Prostate Cancer

Free Subscription 29.07.2024 2 BJU Int 1 BMC Urol 2 Cancer 2 Eur Urol 1 Int J Radiat Oncol Biol Phys 1 J Clin Oncol 1 J Natl Cancer Inst 2 J Nucl Med 2 J Urol 1 JAMA 1 Magn Reson Med 1 PLoS One 1 Proc Natl Acad Sci U S A 4 Prostate 2 Urology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BJU Int

1. DAUNGSUPAWONG H, Wiwanitkit V
   RE: 'The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers'.
   BJU Int. 2024 Jul 26. doi: 10.1111/bju.16489.
   PubMed        
   
   
2. BANCROFT EK
   Response to BJU-2024-0780: RE: The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers.
   BJU Int. 2024 Jul 26. doi: 10.1111/bju.16490.
   PubMed        
   
   

   
   BMC Urol

3. DIVEN M, Ballman K, Marciscano A, Barbieri C, et al
   Radiation therapy and IRreversible electroporation for intermediate risk prostate cancer (RTIRE).
   BMC Urol. 2024;24:151.
   PubMed         Abstract available
   
   

   
   Cancer

4. LEE YHA, Kai Chan JS, Leung CH, Liu AQ, et al
   Comparison of infection risk between enzalutamide and abiraterone in patients with prostate cancer.
   Cancer. 2024 Jul 21. doi: 10.1002/cncr.35472.
   PubMed         Abstract available
   
   
5. MEAGHER M, Morgan K, Deshler L, Riviere P, et al
   Prostate cancer in transgender women: A propensity score-matched analysis of disease severity and survival.
   Cancer. 2024 Jul 21. doi: 10.1002/cncr.35469.
   PubMed         Abstract available
   
   

   
   Eur Urol

6. PARK H, Chen DC, Mazzone E, Grummet J, et al
   Re: Biomarker vs MRI-Enhanced Strategies for Prostate Cancer Screening. The STHLM3-MRI Randomized Clinical Trial.
   Eur Urol. 2024 Jul 19:S0302-2838(24)02452-7. doi: 10.1016/j.eururo.2024.
   PubMed        
   
   
7. MAZZONE E, Perera S, Neti AL, Chen DC, et al
   Re: [(177)Lu]Lu-PSMA-617 plus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer (ENZA-p): An Open-label, Multicentre, Randomised, Phase 2 Trial.
   Eur Urol. 2024 Jul 19:S0302-2838(24)02450-3. doi: 10.1016/j.eururo.2024.
   PubMed        
   
   

   
   Int J Radiat Oncol Biol Phys

8. ODEN J, Eriksson K, Pavoni B, Crezee H, et al
   A Novel Framework for Thermoradiotherapy Treatment Planning.
   Int J Radiat Oncol Biol Phys. 2024;119:1530-1544.
   PubMed         Abstract available
   
   

   
   J Clin Oncol

9. VIGNESWARAN HT, Eklund M, Discacciati A, Nordstrom T, et al
   Stockholm3 in a Multiethnic Cohort for Prostate Cancer Detection (SEPTA): A Prospective Multicentered Trial.
   J Clin Oncol. 2024 Jul 22:JCO2400152. doi: 10.1200/JCO.24.00152.
   PubMed         Abstract available
   
   

   
   J Natl Cancer Inst

10. FARAJ KS, Oerline M, Kaufman SR, Dall C, et al
    Adverse events in men with advanced prostate cancer treated with androgen biosynthesis inhibitors and androgen receptor inhibitors.
    J Natl Cancer Inst. 2024 Jul 25:djae155. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Nucl Med

11. DUIN JJ, de Barros HA, van Leeuwen PJ, van der Poel HG, et al
    Reply: Considerations Surrounding the Sentinel Lymph Node in Prostate Cancer and Unanswered Questions.
    J Nucl Med. 2024 Jul 25:jnumed.124.267658. doi: 10.2967/jnumed.124.267658.
    PubMed        
    
    
12. AH-THIANE L, Ferrer L, Supiot S, Rousseau C, et al
    Considerations Surrounding the Sentinel Lymph Node in Prostate Cancer and Unanswered Questions.
    J Nucl Med. 2024 Jul 25:jnumed.124.267477. doi: 10.2967/jnumed.124.267477.
    PubMed        
    
    

    
    J Urol

13. ROY S, Sun Y, Chi KN, Ong M, et al
    Early PSA Response by 6 Months is Predictive of Treatment Effect in Metastatic Hormone Sensitive Prostate Cancer: An Exploratory Analysis of TITAN Trial.
    J Urol. 2024 Jul 26:101097JU0000000000004158. doi: 10.1097/JU.0000000000004158.
    PubMed         Abstract available
    
    
14. MAI Z, Yan W
    Letter: Comparing Magnetic Resonance Imaging and Prostate-Specific Membrane Antigen-Positron Emission Tomography for Prediction of Extraprostatic Extension of Prostate Cancer and Surgical Guidance: A Prospective Nonrandomized Clinical Trial.
    J Urol. 2024 Jul 25:101097JU0000000000004155. doi: 10.1097/JU.0000000000004155.
    PubMed        
    
    

    
    JAMA

15. NIK-AHD F, De Hoedt AM, Butler C, Anger JT, et al
    Prostate-Specific Antigen Values in Transgender Women Receiving Estrogen.
    JAMA. 2024;332:335-337.
    PubMed        
    
    

    
    Magn Reson Med

16. SAHIN S, Garnaes MF, Bennett A, Dwork N, et al
    A pharmacokinetic model for hyperpolarized (13)C-pyruvate MRI when using metabolite-specific bSSFP sequences.
    Magn Reson Med. 2024;92:1698-1713.
    PubMed         Abstract available
    
    

    
    PLoS One

17. ROTH D, Safi M, Vilhelmsson Timmermand O, Sereti E, et al
    Evaluation of superficial xenograft volume estimation by ultrasound and caliper against MRI in a longitudinal pre-clinical radiotherapeutic setting.
    PLoS One. 2024;19:e0307558.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

18. PORNOUR M, Jeon HY, Ryu H, Khadka S, et al
    USP11 promotes prostate cancer progression by up-regulating AR and c-Myc activity.
    Proc Natl Acad Sci U S A. 2024;121:e2403331121.
    PubMed         Abstract available
    
    

    
    Prostate

19. SCHMIT S, Malshy K, Ochsner A, Golijanin B, et al
    Lower urinary tract symptoms in elderly men: Considerations for prostate cancer testing.
    Prostate. 2024 Jul 25. doi: 10.1002/pros.24772.
    PubMed         Abstract available
    
    
20. HIMMELSBACH R, Hacklander A, Weishaar M, Morlock J, et al
    Retrospective analysis of the learning curve in perineal robot-assisted prostate biopsy.
    Prostate. 2024;84:1165-1172.
    PubMed         Abstract available
    
    
21. OZKAYA M, Simsekoglu MF, Kalender G, Sahin KC, et al
    Clinical and histopathological parameters in transrectal ultrasound-guided biopsies associated with tumor upgrading after radical prostatectomy: A comparative analysis of risk groups.
    Prostate. 2024;84:1146-1156.
    PubMed         Abstract available
    
    
22. BARRIERE H, Kaulanjan K, Stempfer G, Mollard P, et al
    Overall and metastasis-free survival of Afro-Caribbean patients with biochemical recurrence after radical prostatectomy.
    Prostate. 2024;84:1112-1118.
    PubMed         Abstract available
    
    

    
    Urology

23. PETTENUZZO G, Ditonno F, Cannoletta D, Morgantini L, et al
    Single Port Radical Prostatectomy as a Viable Option for Highly Complex Patients: A Single Center Experience.
    Urology. 2024;189:55-63.
    PubMed         Abstract available
    
    
24. APONTE-COLON DA, Creviston A, Abern M, Routh JC, et al
    Radiation-induced Sarcoma of the Prostate After Treatment for Rhabdomyosarcoma.
    Urology. 2024;189:e1-e3.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.